Voyager Therapeutics (NASDAQ:VYGR) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

VYGR has been the subject of a number of other reports. Cantor Fitzgerald started coverage on Voyager Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price objective for the company. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. Wedbush initiated coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target for the company. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $15.97.

Voyager Therapeutics Stock Down 1.4 %

NASDAQ:VYGR opened at $5.52 on Monday. The stock has a market cap of $301.54 million, a P/E ratio of 7.77 and a beta of 0.93. The business’s 50-day moving average price is $5.82 and its two-hundred day moving average price is $6.57. Voyager Therapeutics has a twelve month low of $4.99 and a twelve month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the previous year, the company earned ($0.59) EPS. On average, equities research analysts expect that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold 10,778 shares of company stock valued at $58,548 over the last quarter. 4.53% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Erste Asset Management GmbH bought a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $6,192,000. Barclays PLC boosted its stake in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after acquiring an additional 37,398 shares in the last quarter. Verition Fund Management LLC bought a new position in shares of Voyager Therapeutics during the third quarter valued at approximately $216,000. Massachusetts Financial Services Co. MA increased its stake in shares of Voyager Therapeutics by 19.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock valued at $1,005,000 after purchasing an additional 28,333 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Voyager Therapeutics by 26.9% in the 3rd quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after purchasing an additional 19,622 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.